Novartis extends commitment to help achieve final elimination of leprosy
- Details
- Category: Novartis
Novartis will continue its work with the World Health Organization (WHO) toward a world free of leprosy by extending its drug donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020.
Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010.
Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back® Alzheimer's Initiative introduced the Alzheimer's Challenge 2012 at the Care Innovations Summit in Washington, D.C.
Bristol-Myers Squibb delivers solid fourth quarter capping a year highlighted by new product approvals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced solid financial results for the fourth quarter of 2011. This concludes a year in which the Company received important new product approvals for YERVOY® and NULOJIX® in both the U.S. and Europe, and ELIQUIS® in Europe for the prevention of venous thromboembolic events.
Amgen to Acquire Micromet
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.
Novartis delivers strong underlying financial performance in 2011
- Details
- Category: Novartis
Novartis' net sales rose 4% (+5% cc) to USD 14.8 billion in the fourth quarter. The strengthening of the US dollar against most major currencies negatively impacted sales by 1 percentage point.
Abbott reports double-digit ongoing earnings-per-share growth in fourth quarter and full-year 2011
- Details
- Category: Abbott
Abbott's worldwide sales increased 4.1 percent to $10.4 billion, including a favorable 0.2 percent effect of foreign exchange. Emerging markets sales were $2.5 billion, representing nearly 25 percent of total sales, with particularly strong growth in Nutritionals, Vascular and Diagnostics.
More Pharma News ...
- Novo Nordisk establishes type 1 diabetes R&D center in Seattle
- Roche supports cancer care development program in Ethiopia
- Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
- Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients
- Novartis receives approval for Lucentis® and launches Galvus® in China
- Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
- Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio